Alkermes plc (ALKS)
NASDAQ: ALKS · Real-Time Price · USD
40.80
+0.65 (1.62%)
Sep 29, 2026, 4:00 PM EDT - Market closed
Alkermes Revenue
Alkermes had revenue of $496.01M in the quarter ending June 30, 2026, with 26.97% growth. This brings the company's revenue in the last twelve months to $1.67B, up 10.79% year-over-year. In the year 2025, Alkermes had annual revenue of $1.48B, down -5.25%.
Revenue (ttm)
$1.67B
Revenue Growth
+10.79%
P/S Ratio
4.10
Revenue / Employee
$813,489
Employees
2,050
Market Cap
6.84B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.48B | -81.73M | -5.25% |
| Dec 31, 2024 | 1.56B | -105.77M | -6.36% |
| Dec 31, 2023 | 1.66B | 551.61M | 49.61% |
| Dec 31, 2022 | 1.11B | -61.96M | -5.28% |
| Dec 31, 2021 | 1.17B | 135.00M | 13.00% |
| Dec 31, 2020 | 1.04B | -132.19M | -11.29% |
| Dec 31, 2019 | 1.17B | 76.67M | 7.01% |
| Dec 31, 2018 | 1.09B | 190.90M | 21.13% |
| Dec 31, 2017 | 903.37M | 157.68M | 21.15% |
| Dec 31, 2016 | 745.69M | 117.36M | 18.68% |
| Dec 31, 2015 | 628.34M | 9.55M | 1.54% |
| Dec 31, 2014 | 618.79M | 464.31M | 300.57% |
| Dec 31, 2013 | 154.48M | -421.07M | -73.16% |
| Mar 31, 2013 | 575.55M | 185.57M | 47.59% |
| Mar 31, 2012 | 389.98M | 203.34M | 108.95% |
| Mar 31, 2011 | 186.64M | 8.36M | 4.69% |
| Mar 31, 2010 | 178.28M | -148.56M | -45.45% |
| Mar 31, 2009 | 326.84M | 86.12M | 35.78% |
| Mar 31, 2008 | 240.72M | 752.00K | 0.31% |
| Mar 31, 2007 | 239.97M | 73.36M | 44.04% |
| Mar 31, 2006 | 166.60M | 90.48M | 118.85% |
| Mar 31, 2005 | 76.13M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Elanco Animal Health | 5.02B |
| Dr. Reddy's Laboratories | 3.50B |
| Neurocrine Biosciences | 3.37B |
| Amneal Pharmaceuticals | 3.12B |
| Hims & Hers Health | 2.58B |
| Lantheus Holdings | 1.56B |
| Kiniksa Pharmaceuticals International, | 840.85M |
| Supernus Pharmaceuticals | 830.44M |
ALKS News
- 5 days ago - Alkermes resumed with a Neutral at Goldman Sachs - TheFly
- 7 days ago - Alkermes price target raised to $61 from $58 at Baird - TheFly
- 8 days ago - Alkermes data show measurable improvements in ADHD, says H.C. Wainwright - TheFly
- 8 days ago - Alkermes jumps 8% to $46.99 after Phase I adult ADHD data - TheFly
- 8 days ago - Alkermes announces Phase 1b results of ALKS 7290 in ADHD - TheFly
- 8 days ago - Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) - Business Wire
- 13 days ago - Alkermes announces appointment of Whitaker to Board of Directors - TheFly
- 13 days ago - Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors - Business Wire